JAK/HDAC-IN-4

• UNSPSC Description:

  JAK/HDAC-IN-4 (compound 11 i) is a JAK/HDAC inhibitor with the IC50 values of 0.49 nM and 12 nM for JAK2 and HDAC6, respectively. JAK/HDAC-IN-4 inhibits the cell proliferation and the production of nitric oxide. JAK/HDAC-IN-4 ameliorates psoriasis-like skin lesions in an Imiquimod (HY-B0180)-induced murine model with low toxicity[1].

• Target Antigen:

  HDAC; JAK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/jak-hdac-in-4.html

• Smiles:

  O=S(NC1=CC=C(C=C1)C2=NC(NC3=CC=C(C=C3)N4CCN(CC4)CC(NC5=CC=C(C=C5)C(NO)=O)=O)=NC=C2)(C)=O

• Molecular Weight:

  616.69

• References & Citations:

  [1]Hu W, et al. Discovery of Janus Kinase and Histone Deacetylase Dual Inhibitors as a New Strategy to Treat Psoriasis. J Med Chem. 2024 Nov 14;67(21):19267-19281.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported